{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T22:18:41Z","timestamp":1768515521228,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,3,6]],"date-time":"2015-03-06T00:00:00Z","timestamp":1425600000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s12032-015-0558-2","type":"journal-article","created":{"date-parts":[[2015,3,5]],"date-time":"2015-03-05T02:53:05Z","timestamp":1425523985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["G protein-coupled estrogen receptor (GPER) mediates NSCLC progression induced by 17\u03b2-estradiol (E2) and selective agonist G1"],"prefix":"10.1007","volume":"32","author":[{"given":"Changyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongde","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hexiao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixiao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianmiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,6]]},"reference":[{"key":"558_CR1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9\u201329.","journal-title":"CA Cancer J Clin"},{"key":"558_CR2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.seminoncol.2013.12.009","volume":"41","author":"JM Siegfried","year":"2014","unstructured":"Siegfried JM, Stabile LP. Estrogenic steroid hormones in lung cancer. Semin Oncol. 2014;41:5\u201316.","journal-title":"Semin Oncol"},{"key":"558_CR3","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0140-6736(09)61526-9","volume":"374","author":"RT Chlebowski","year":"2009","unstructured":"Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women\u2019s Health Initiative Trial): a post hoc analysis of a randomised controlled trial. Lancet. 2009;374:1243\u201351.","journal-title":"Lancet"},{"key":"558_CR4","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/cncr.25638","volume":"117","author":"C Bouchardy","year":"2011","unstructured":"Bouchardy C, Benhamou S, Schaffar R, et al. Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Cancer. 2011;117:1288\u201395.","journal-title":"Cancer"},{"key":"558_CR5","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1200\/JCO.2009.25.9739","volume":"28","author":"CG Slatore","year":"2010","unstructured":"Slatore CG, Chien JW, Au DH, Satia JA, White E. Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J Clin Oncol. 2010;28:1540\u20136.","journal-title":"J Clin Oncol"},{"key":"558_CR6","first-page":"3509","volume":"82","author":"AW Brandenberger","year":"1997","unstructured":"Brandenberger AW, Tee MK, Lee JY, Chao V, Jaffe RB. Tissue distribution of estrogen receptors alpha (ER-alpha) and beta (ER-beta) mRNA in the midgestational human fetus. J Clin Endocrinol Metab. 1997;82:3509\u201312.","journal-title":"J Clin Endocrinol Metab"},{"key":"558_CR7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jsbmb.2009.05.004","volume":"116","author":"PA Hershberger","year":"2009","unstructured":"Hershberger PA, Stabile LP, Kanterewicz B, et al. Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44\/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. J Steroid Biochem Mol Biol. 2009;116:102\u20139.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"558_CR8","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1210\/me.2008-0431","volume":"23","author":"G Zhang","year":"2009","unstructured":"Zhang G, Liu X, Farkas AM, et al. Estrogen receptor beta functions through nongenomic mechanisms in lung cancer cells. Mol Endocrinol. 2009;23:146\u201356.","journal-title":"Mol Endocrinol"},{"key":"558_CR9","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1158\/0008-5472.CAN-04-1872","volume":"65","author":"LP Stabile","year":"2005","unstructured":"Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR. Siegfried JM Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res. 2005;65:1459\u201370.","journal-title":"Cancer Res"},{"key":"558_CR10","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1007\/s12032-012-0198-8","volume":"29","author":"H Tang","year":"2012","unstructured":"Tang H, Liao Y, Chen G, et al. Estrogen upregulates the IGF-1 signaling pathway in lung cancer through estrogen receptor-beta. Med oncol. 2012;29:2640\u20138 (Northwood, London, England).","journal-title":"Med oncol"},{"key":"558_CR11","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/ijc.28262","volume":"133","author":"H Tang","year":"2013","unstructured":"Tang H, Liao Y, Xu L, et al. Estrogen and insulin-like growth factor 1 synergistically promote the development of lung adenocarcinoma in mice. Int J Cancer. 2013;133:2473\u201382.","journal-title":"Int J Cancer"},{"key":"558_CR12","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nrendo.2011.122","volume":"7","author":"ER Prossnitz","year":"2011","unstructured":"Prossnitz ER, Barton M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol. 2011;7:715\u201326.","journal-title":"Nat Rev Endocrinol"},{"key":"558_CR13","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1126\/science.1106943","volume":"307","author":"CM Revankar","year":"2005","unstructured":"Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005;307:1625\u201330 (New York, NY).","journal-title":"Science"},{"key":"558_CR14","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1210\/en.2004-1064","volume":"146","author":"P Thomas","year":"2005","unstructured":"Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology. 2005;146:624\u201332.","journal-title":"Endocrinology"},{"key":"558_CR15","doi-asserted-by":"crossref","first-page":"27008","DOI":"10.1074\/jbc.M403588200","volume":"279","author":"M Maggiolini","year":"2004","unstructured":"Maggiolini M, Vivacqua A, Fasanella G, et al. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004;279:27008\u201316.","journal-title":"J Biol Chem"},{"key":"558_CR16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ygyno.2009.05.015","volume":"114","author":"HO Smith","year":"2009","unstructured":"Smith HO, Arias-Pulido H, Kuo DY, et al. GPR30 predicts poor survival for ovarian cancer. Gynecol Oncol. 2009;114:465\u201371.","journal-title":"Gynecol Oncol"},{"issue":"386","key":"558_CR17","first-page":"e381","volume":"196","author":"HO Smith","year":"2007","unstructured":"Smith HO, Leslie KK, Singh M, et al. GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol. 2007;196(386):e381\u20139 discussion 386 e389-311, 2007.","journal-title":"Am J Obstet Gynecol."},{"key":"558_CR18","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1210\/mend.14.10.0532","volume":"14","author":"EJ Filardo","year":"2000","unstructured":"Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol. 2000;14:1649\u201360.","journal-title":"Mol Endocrinol"},{"key":"558_CR19","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1158\/0008-5472.CAN-06-2909","volume":"67","author":"L Albanito","year":"2007","unstructured":"Albanito L, Madeo A, Lappano R, et al. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res. 2007;67:1859\u201366.","journal-title":"Cancer Res"},{"key":"558_CR20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1210\/me.2005-0280","volume":"20","author":"A Vivacqua","year":"2006","unstructured":"Vivacqua A, Bonofiglio D, Recchia AG, et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol. 2006;20:631\u201346.","journal-title":"Mol Endocrinol"},{"key":"558_CR21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev.physiol.59.1.365","volume":"59","author":"M Wehling","year":"1997","unstructured":"Wehling M. Specific, nongenomic actions of steroid hormones. Annu Rev Physiol. 1997;59:365\u201393.","journal-title":"Annu Rev Physiol"},{"key":"558_CR22","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1186\/1471-2407-12-624","volume":"12","author":"VR Jala","year":"2012","unstructured":"Jala VR, Radde BN, Haribabu B, Klinge CM. Enhanced expression of G-protein coupled estrogen receptor (GPER\/GPR30) in lung cancer. BMC Cancer. 2012;12:624.","journal-title":"BMC Cancer"},{"key":"558_CR23","doi-asserted-by":"crossref","unstructured":"Garon E, Siegfried JM, Dubinett SM, et al. Results of TORI-L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E+fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC). In: Proceedings of the 104th annual meeting of the american association for cancer research. Philadelphia (PA): AACR; 2013; abstract 4664, 6\u201310 Apr 2013 Washington DC.","DOI":"10.1158\/1538-7445.AM2013-4664"},{"key":"558_CR24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10549-012-1968-x","volume":"134","author":"R Girgert","year":"2012","unstructured":"Girgert R, Emons G, Grundker C. Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy. Breast Cancer Res Treat. 2012;134:199\u2013205.","journal-title":"Breast Cancer Res Treat"},{"key":"558_CR25","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1006\/geno.1997.4972","volume":"45","author":"C Carmeci","year":"1997","unstructured":"Carmeci C, Thompson DA, Ring HZ, Francke U, Weigel RJ. Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics. 1997;45:607\u201317.","journal-title":"Genomics"},{"key":"558_CR26","doi-asserted-by":"crossref","first-page":"6359","DOI":"10.1158\/1078-0432.CCR-06-0860","volume":"12","author":"EJ Filardo","year":"2006","unstructured":"Filardo EJ, Graeber CT, Quinn JA, et al. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res. 2006;12:6359\u201366.","journal-title":"Clin Cancer Res"},{"key":"558_CR27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/153303460900800308","volume":"8","author":"G Tu","year":"2009","unstructured":"Tu G, Hu D, Yang G, Yu T. The correlation between GPR30 and clinicopathologic variables in breast carcinomas. Technol Cancer Res Treat. 2009;8:231\u20134.","journal-title":"Technol Cancer Res Treat"},{"key":"558_CR28","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1124\/mol.106.026344","volume":"70","author":"A Vivacqua","year":"2006","unstructured":"Vivacqua A, Bonofiglio D, Albanito L, et al. 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30. Mol Pharmacol. 2006;70:1414\u201323.","journal-title":"Mol Pharmacol"},{"key":"558_CR29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10549-014-2936-4","volume":"145","author":"M Sjostrom","year":"2014","unstructured":"Sjostrom M, Hartman L, Grabau D, et al. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer. Breast Cancer Res Treat. 2014;145:61\u201371.","journal-title":"Breast Cancer Res Treat"},{"key":"558_CR30","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.bbrc.2012.02.161","volume":"420","author":"GQ Du","year":"2012","unstructured":"Du GQ, Zhou L, Chen XY, Wan XP, He YY. The G protein-coupled receptor GPR30 mediates the proliferative and invasive effects induced by hydroxytamoxifen in endometrial cancer cells. Biochem Biophys Res Commun. 2012;420:343\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"558_CR31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jneuroim.2009.06.023","volume":"214","author":"E Blasko","year":"2009","unstructured":"Blasko E, Haskell CA, Leung S, et al. Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis. J Neuroimmunol. 2009;214:67\u201377.","journal-title":"J Neuroimmunol"},{"key":"558_CR32","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/emboj.2008.304","volume":"28","author":"DP Pandey","year":"2009","unstructured":"Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J. 2009;28:523\u201332.","journal-title":"EMBO J"},{"key":"558_CR33","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1158\/0008-5472.CAN-08-1622","volume":"69","author":"BC Lin","year":"2009","unstructured":"Lin BC, Suzawa M, Blind RD, et al. Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation. Cancer Res. 2009;69:5415\u201323.","journal-title":"Cancer Res"},{"key":"558_CR34","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/JTO.0b013e31827d525c","volume":"8","author":"EB Garon","year":"2013","unstructured":"Garon EB, Pietras RJ, Finn RS, et al. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol. 2013;8:270\u20138.","journal-title":"J Thorac Oncol"},{"key":"558_CR35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0960-0760(01)00190-X","volume":"80","author":"EJ Filardo","year":"2002","unstructured":"Filardo EJ. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol. 2002;80:231\u20138.","journal-title":"J Steroid Biochem Mol Biol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-015-0558-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-015-0558-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-015-0558-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T13:36:19Z","timestamp":1566394579000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-015-0558-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,6]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["558"],"URL":"https:\/\/doi.org\/10.1007\/s12032-015-0558-2","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,6]]},"article-number":"104"}}